RxDoctor Payments Data

Tara Chang, MD

Nephrology · Stanford, CANPI 1437166592

Payments from drug & device makers

$42,952in general payments, 2019–2025

Across 43 payments — averaging $998.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$19K
  • AstraZeneca$16K
  • Astrazeneca UK Limited$7K
  • Eli Lilly$675
  • Travere Therapeutics, Inc.$138
  • Ablative Solutions, Inc.$125
  • plus $216 from 2 others
$68,922in research payments, 2019–2025

Across 144 payments — averaging $478.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$64K
  • Eli Lilly$3K
  • Gilead$2K

What the payments were for

  • Consulting fees$39,26993%
  • Travel & lodging$1,6104%
  • Food & beverage$1,3923%
  • Education$60%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer12$19,320
AstraZeneca(2 entities)21$15,748
Astrazeneca UK Limited3$6,730
Eli Lilly1$675
Travere Therapeutics, Inc.3$138
Ablative Solutions, Inc.1$125
Astrazeneca AB1$120
Gilead1$96

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,952 in reported general payments places this provider in the 85th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$64,360
Medicare patients
208
Services billed
583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol42$55,822
JardianceEmpagliflozin32$40,294
AranespDarbepoetin Alfa In Polysorbat12$26,545
VeltassaPatiromer Calcium Sorbitex11$26,228
ProcritEpoetin Alfa11$5,113
Losartan Potassium48$658
Doxazosin Mesylate24$531
Calcitriol13$514
Carvedilol44$421
Spironolactone33$412
Potassium Chloride16$374
Chlorthalidone31$366
Nifedipine ErNifedipine12$331
Amlodipine Besylate47$310
Allopurinol26$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$15,748$55,82242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,341 nephrology providers in California.

Other nephrology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →